ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings Inc (SHPH)

1.15
-0.015
(-1.29%)
At close: October 07 4:00PM
1.14
-0.01
( -0.87% )
After Hours: 5:07PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.14
Bid
1.13
Ask
1.14
Volume
73,471
1.13 Day's Range 1.28
1.13 52 Week Range 5.352
Market Cap
Previous Close
1.165
Open
1.19
Last Trade Time
17:07:46
Financial Volume
$ 87,021
VWAP
1.1844
Average Volume (3m)
774,183
Shares Outstanding
2,226,951
Dividend Yield
-
PE Ratio
-0.39
Earnings Per Share (EPS)
-2.96
Revenue
-
Net Profit
-6.59M

About Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surg... Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Shuttle Pharmaceuticals Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SHPH. The last closing price for Shuttle Pharmaceuticals was $1.17. Over the last year, Shuttle Pharmaceuticals shares have traded in a share price range of $ 1.13 to $ 5.352.

Shuttle Pharmaceuticals currently has 2,226,951 shares outstanding. The market capitalization of Shuttle Pharmaceuticals is $2.59 million. Shuttle Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.39.

SHPH Latest News

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (β€œShuttle Pharma”), a discovery and development stage specialty pharmaceutical company...

Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease

GAITHERSBURG, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer...

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (β€œShuttle Pharma”), a discovery and development stage specialty pharmaceutical company...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2-14.92537313431.341.36991.13336301.21721384CS
4-0.47-29.19254658391.611.841.13888681.50923668CS
12-2.2536-66.40735502123.39364.161.137741832.62978634CS
26-2.22-66.07142857143.364.71041.133934682.70706236CS
52-3.164-73.51301115244.3045.3521.132547742.94671726CS
156-191.26-99.4074844075192.41010.081.1376967853.43115627CS
260-191.26-99.4074844075192.41010.081.1376967853.43115627CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
OTRKOntrak Inc
$ 2.81
(54.40%)
595.09k
BLMZBloomZ Inc
$ 0.944
(38.01%)
82.98k
SNALSnail Inc
$ 1.9701
(17.97%)
2M
VINCVincerx Inc
$ 0.78
(11.75%)
4.42M
VIVKVivakor Inc
$ 1.73
(10.90%)
25.97k
DBGIDigital Brands Group Inc
$ 0.20
(-29.33%)
1.99M
ZJKZJK Industrial Company Ltd
$ 5.00
(-26.47%)
578.9k
HWHHWH International Inc
$ 0.835
(-16.50%)
36.28k
CETXCemtrex Inc
$ 1.15
(-16.06%)
2.11M
CHSNChanson International Holding
$ 11.08
(-9.48%)
83.7k
VINCVincerx Inc
$ 0.78
(11.75%)
4.42M
NVDANVIDIA Corporation
$ 128.15
(0.34%)
2.48M
XPONExpion360 Inc
$ 0.0339
(-0.88%)
2.41M
CETXCemtrex Inc
$ 1.15
(-16.06%)
2.11M
SNALSnail Inc
$ 1.9701
(17.97%)
2M

SHPH Discussion

View Posts
SmallCapStockAlert SmallCapStockAlert 5 days ago
$SHPH beginning P2 Clinical trial on Ropidoxuridine that is like radiation therapy on steroids. Could be big winner from here on out. https://richardacavalli.wixsite.com/greenplanetmicrocaps/nexgen-cancer-radiation
👍️ 1
SmallCapStockAlert SmallCapStockAlert 2 weeks ago
$SHPH is getting big money that is expected to create a blockbuster for them. Price looks really attractive.
πŸ‘οΈ0
glenn1919 glenn1919 1 month ago
SHPH...............................................................https://stockcharts.com/h-sc/ui?s=SHPH&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Awl416 Awl416 1 month ago
Don’t blink…
👍️ 1
chompers chompers 1 month ago
This is setting for a squeeze......
πŸ‘οΈ0
Awl416 Awl416 1 month ago
LOL
πŸ‘οΈ0
Awl416 Awl416 1 month ago
Halt…
πŸ‘οΈ0
Awl416 Awl416 1 month ago
1.7 PM
πŸ‘οΈ0
Awl416 Awl416 1 month ago
Welp
πŸ‘οΈ0
Triple nickle Triple nickle 1 month ago
SHPH 2.87 A/H
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
SHPH new 52 week low
πŸ‘οΈ0
SmallCapStockAlert SmallCapStockAlert 3 months ago
needs big money for upcoming trials which means huge numbers of shares hitting the market soon. STRONG SELL!
πŸ‘οΈ0
konshe konshe 3 months ago
I am sold out in premarket at 0.57 with news. feel luck. But Market open is different reaction to news. Very strange
πŸ‘οΈ0
Awl416 Awl416 3 months ago
Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
πŸ‘οΈ0
konshe konshe 3 months ago
Moving up, looks good.
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
SHPH new 52 week low
πŸ‘οΈ0
TheFinalCD TheFinalCD 9 months ago
https://ih.advfn.com/stock-market/NASDAQ/shuttle-pharmaceuticals-SHPH/stock-news/92982458/form-8-k-current-report
πŸ‘οΈ0
tw0122 tw0122 9 months ago
Boom .62
πŸ‘οΈ0
konshe konshe 11 months ago
MMs are playing game to sell or buy 1 shares to control PPS.
πŸ‘οΈ0
konshe konshe 12 months ago
Unbelievable SHPH from $8 up to $126, then from $126 down to $0.48. What is real value? Now MC is only $8mm???? MMs are playing big game!!!
πŸ‘οΈ0
Monksdream Monksdream 12 months ago
SHPH new 52 week low
πŸ‘οΈ0
konshe konshe 1 year ago
ready to rebound from the bottom
πŸ‘οΈ0
konshe konshe 1 year ago
news out today:
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that TCG GreenChem has successfully completed the initial manufacturing campaign for the active pharmaceutical ingredient (API) of Ropidoxuridine for use in the Company's upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy.

"Shuttle has been working concomitantly with TCG GreenChem to manufacture API and University of Iowa Pharmaceuticals to develop the formulation and packaging of the drug product into capsules for clinical use. Today's announcement of successfully completing the API manufacturing is an important step in the advancement Ropidoxuridine, our lead clinical sensitizer drug candidate, towards the commencement of our upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy," commented Shuttle Pharma's Chairman and CEO, Anatoly Dritschilo, M.D.

In addition, Shuttle's recent request for a Type B pre-IND meeting with the FDA for guidance on the proposed Phase II clinical trial has been approved with a goal of receiving written responses from the FDA by September 18, 2023. With this, the Company believes it remains on track to commence its Phase II clinical study in the fourth quarter of 2023.
πŸ‘οΈ0
konshe konshe 1 year ago
This news delayed one month already, It should be out soon, with this news PPS could be explode
👍️ 1
konshe konshe 1 year ago
See afternoon buy up as usual.
πŸ‘οΈ0
makinezmoney makinezmoney 1 year ago
$SHPH: Tiny lil bounce here at 1.12 now


Sooooooooooooooooooooo...................... can it get to $3.50 ???


We shall see


GO $SHPH
πŸ‘οΈ0
konshe konshe 1 year ago
Pay attention to these sentences, PPS will explode again.


With Ropidoxuridine, we are finalizing details to submit the final protocol details to the FDA at the end of the second quarter of 2023 with commencement of the Phase II clinical trial in brain cancer patients commencing shortly thereafter.
πŸ‘οΈ0
konshe konshe 1 year ago
Shuttle Pharmaceuticals Provides Q1 2023 Corporate Update
3w
+2.88%
Recent Highlights

Shuttle Pharma continues to execute on the necessary steps to advance Ropidoxuridine, the Company's lead clinical sensitizer drug candidate, towards the commencement of its upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy with an expectation of pre-IND application submission to the FDA by the end of the second quarter of 2023.
Entered into agreements with TCG GreenChem, Inc. and UI Pharmaceuticals for drug manufacture and formulation development of Ropidoxuridine, the Company's lead clinical sensitizer drug candidate, for use in the Company's upcoming Phase II clinical trial evaluating Ropidoxuridine in combination with radiation therapy for the treatment of glioblastoma.
Engaged Theradex Oncology, a leading clinical research organization, to help prepare for its upcoming clinical study of Ropidoxuridine.
Entered into an agreement to lease new laboratory and office space, commencing in June 2023, to assist in furthering the development of the Company's lead drug candidates and accelerate broader diagnostic capabilities on predictive biomarkers.
Entered a research agreement with Georgetown University focused on the evaluation of the Company's lead HDAC6 inhibitor candidate, SP-2-225, evaluating the anti-tumor effect of the combination of SP-2-225 and RT in a syngeneic breast cancer model.
Shuttle Pharma was awarded U.S. Patent No. 11,654,157, "Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With Radiation," which was issued by the U.S. Patent and Trademark Office on May 23, 2023.
Published manuscripts discussing prostate cancer cell lines derived from African American men for precision medicine and immune responses taking place in patients after radiation therapy for cancer.
Awarded patents in the U.S. and Hong Kong for its radiation sensitizing HDAC inhibitor technology platform.
Appointed Dr. Bette Jacobs to its Board of Directors as an independent director.
Rang the Nasdaq opening bell in January 2023.
Closed on private placement of $4.3 Million of Senior Secured Convertible Note and Warrants to purchase 1.018 million shares of common stock in exchange for $4.0 million investment.
At March 31, 2023, the Company had a working capital balance of $9 million. The Company anticipates that it has sufficient capital to fund operations into the first quarter of 2025.
"Shuttle Pharma is advancing our mission to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of Radiation Therapy while limiting the late effects of radiation in cancer treatment," commented Shuttle Pharma's Chairman and CEO, Anatoly Dritschilo, M.D. "During the first quarter, we made tangible progress advancing our pipeline, including Ropidoxuridine, our lead clinical drug candidate, which sensitizes rapidly growing cancer cells and, our various selective HDAC (histone deacetylase) inhibitors – which sensitize cancer cells and stimulate the immune system. With Ropidoxuridine, we are finalizing details to submit the final protocol details to the FDA at the end of the second quarter of 2023 with commencement of the Phase II clinical trial in brain cancer patients commencing shortly thereafter. Additionally, we are advancing pre-clinical work to support our IND-enabling studies in 2023 with a goal to submit an investigational new drug application (IND) for the selective HDAC6 inhibitor and initiation of a Phase I clinical trial in 2024. We look forward to an exciting 2023 as we advance our immuno-oncology and radio-oncology solutions."
πŸ‘οΈ0
konshe konshe 1 year ago
In siders own 47% shares
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
mAybe
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
insert dd
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
they pop big then consolidate 2 ,, 3 or 4 weeks then run again -insert DD-
πŸ‘οΈ0
konshe konshe 1 year ago
looks like ready to move north
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
https://www.barchart.com/stocks/quotes/SHPH/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=SHPH&grid=1&height=500&studyheight=100
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
watching
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
keeping track of my 50 tickers, big runs, big dips then run higher
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
watching lots of one day wonders
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 year ago
SHPH: THANKS for that!!
πŸ‘οΈ0
konshe konshe 1 year ago
SHPH trading up to $2+ at today's pre market.
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 year ago
SHPH: And THANKS again, Boss!!
πŸ‘οΈ0
subslover subslover 1 year ago
Quarterly Report (10-q)
https://ih.advfn.com/stock-market/NASDAQ/shuttle-pharmaceuticals-SHPH/stock-news/91166889/quarterly-report-10-q
πŸ‘οΈ0
konshe konshe 1 year ago
Short becareful, Charts shows ready to big rebound.
πŸ‘οΈ0
DK11 DK11 1 year ago
Nonstop flight down I mean. This is perfect to short
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
good to short
πŸ‘οΈ0
KeepOn KeepOn 1 year ago
Wow!
πŸ‘οΈ0
DK11 DK11 1 year ago
Yessss Sir, this shuttle is a non-stop flight
πŸ‘οΈ0
Triple nickle Triple nickle 1 year ago
Right thru three bucks imo
πŸ‘οΈ0
Triple nickle Triple nickle 1 year ago
: )
πŸ‘οΈ0
konshe konshe 1 year ago
SHPH News
Shuttle Pharmaceuticals shares are trading higher after it was granted U.S. patent #11654157: Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation.
2h
+98.54%
Digest-only
πŸ‘οΈ0
konshe konshe 1 year ago
where is the news?
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock